News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Analyst action
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
RA Capital Management and its affiliated funds have disclosed an 8.6% beneficial ownership stake in CervoMed Inc. (CRVO), primarily through warrants exercisable for 1,266,143 shares of common stock. This disclosure, based on a SCHEDULE 13G/A filing, indicates that RA Capital, along with Peter Kolchinsky …
CVI Investments, Inc. and Heights Capital Management, Inc. have filed an amended Schedule 13G/A for CervoMed Inc. (CRVO), reporting a 0% beneficial ownership in the company. This filing indicates that both entities collectively hold no shares and possess no voting or dispositive power over …
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.53% in CervoMed Inc. (CRVO), totaling 1,592,863 shares of common stock. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the investment manager, granting them shared …
Generate Biomedicines (NASDAQ: GENB) utilizes machine learning and generative AI for novel therapeutic design and discovery. The company recently reported Q2 2026 earnings, missing analyst estimates, and has a "Moderate Buy" consensus rating with a price target of $25.40, suggesting a 62.4% upside. Its …
Wall Street analysts are showing bullish sentiment towards two healthcare stocks: Orchestra BioMed Holdings (OBIO) and Adagene (ADAG). H.C. Wainwright reiterated a Buy rating for Orchestra BioMed with a $10.00 price target, while LifeSci Capital maintained a Buy rating for Adagene with an $8.00 …
Orchestra BioMed Holdings, Inc. (OBIO) recently reported Q2 results showing revenues significantly below expectations, though statutory losses were in line with forecasts. Analysts have since updated their models, projecting a substantial 99% reduction in 2026 revenues and an increase in per-share losses, indicating a …
A federal judge has granted final approval for a $3.75 million settlement in a securities class action lawsuit against Lifecore Biomedical Inc. Investors accused Lifecore of making false statements about its financial condition and internal accounting controls, which led to a stock price drop …
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Manager of Investor Relations - Stephanie Diaz President and Chief Executive Officer - Paul Josephs Chief Financial Officer - Ryan Lake Full Conference Call Transcript Operator: Good morning, …
CervoMed Inc. (CRVO) has reported significant clinical and regulatory progress for its Phase III-ready drug targeting Dementia with Lewy Bodies (DLB), showing strong data supporting its mechanism and efficacy. The company is also expanding its pipeline into Progressive Supranuclear Palsy (PPA) and Amyotrophic Lateral …
Orchestra BioMed (NASDAQ:OBIO) reported a quarterly loss of $0.38 per share, missing analyst estimates by $0.03. Despite the earnings miss and negative financial metrics, the company's shares increased by 5.2% and insiders purchased a significant amount of stock. Analyst sentiment is mixed but generally …
Orchestra Biomed Holdings (NASDAQ: OBIO) reported second-quarter EPS of $-0.380
This article reports on CytoMed Therapeutics Ltd's (GDTC) SEC Form 144 filing from August 11, 2026. The filing indicates a proposed sale of securities under Rule 144, detailing information about the issuer, securities to be sold (Ordinary Shares acquired on 04/22/2021), and the transaction …
CervoMed reported its second-quarter 2026 results, highlighting a cash position of approximately $24.9 million and a net loss of $6.6 million. The company completed two equity financings in June, raising $20.5 million, extending its cash runway through Q3 2027. CervoMed is strategically focusing on …
This article provides an earnings forecast for Advanced Biomed Inc (ADVB), covering future EPS, revenue, net profit, and EBIT growth estimates. It lists current stock performance metrics and offers a peer comparison with other healthcare companies like CVS Health Corp and HCA Healthcare Inc. …
The average 12-month price target for Orchestra BioMed Holdings, Inc. (OBIO) stock has increased to $12.33, up from $12.17, according to estimates from six analysts. This new target suggests a potential upside of approximately 177% from its closing price on August 10. The consensus …
Orchestra BioMed announced its second-quarter 2026 financial results, highlighting progress in its two cardiovascular programs: AVIM Therapy and Virtue SAB. The company reported that its BACKBEAT trial for AVIM Therapy is on track to meet its target enrollment by Q3 2026, with primary data …
Orchestra BioMed Holdings reported a net loss of $24.1 million in Q2 2026, widening from the previous year, despite an 89% drop in revenue to $88,000. The loss was primarily due to increased research and development expenses for pivotal clinical trials. However, the company …
Canaccord Genuity lowered its price target on CervoMed Inc. to $18 from $27, citing uncertainty regarding funding for the company's lead drug candidate, neflamapimod, despite maintaining a Buy rating. The stock has seen a significant decline, but the firm believes it remains undervalued due …
CervoMed (NASDAQ: CRVO) reported its Q2 2026 financial results, detailing a net loss of $6.6 million and highlighting that its current cash of $24.9 million is expected to fund operations through Q3 2027. The company is prioritizing a strategic partnership to advance its lead …
Orchestra BioMed reported its Q2 2026 financial results, including a net loss of $24.1 million, and provided updates on its pivotal clinical trials. The BACKBEAT Trial for uncontrolled hypertension is on track to enroll 284 patients by Q3 2026, with primary results expected in …
Orchestra BioMed Holdings, Inc. (OBIO) reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a $0.35 loss, though it was an improvement from a $0.5 loss a year ago. The company also missed revenue estimates, posting $0.09 million against …
Search by ticker symbol or company name and select a result to open its chart.